Zomedica Corp

Zomedica Corp has a capital structure with no long-term debt and a debt-to-equity ratio of 0.0, indicating a purely equity-funded operation. The company holds $9.0 million in cash and equivalents, but its operating cash flow is negative at -$17.6 million, and free cash flow is -$74.9 million, reflecting significant cash outflows. The current ratio of 6.78 suggests strong short-term liquidity, but the negative operating and free cash flows indicate ongoing operational challenges. Profitability metrics show a return on equity of -70.94% and a return on assets of -64.44%, both well below industry norms for veterinary health companies. The company reported a net loss of $81.9 million and an operating loss of $84.4 million, indicating a significant decline in profitability compared to industry peers. Zomedica Corp's revenue is concentrated in two segments: Diagnostics and Therapeutic Devices. The Diagnostics segment includes TRUFORMA, VETGuardian, and TRUVIEW products, while the Therapeutic Devices segment includes Assisi Loop and PulseVet products. The company does not disclose geographic revenue breakdowns, but its operations are primarily based in North America. The company's revenue for the latest period was $32.0 million, with no immediate growth signals in the next fiscal year. The negative operating and free cash flows suggest that the company is not generating sufficient cash to sustain operations without external financing. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The risk assessment highlights low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued any recent equity or debt, and there are no signs of near-term dilution pressure. However, the significant negative cash flows and operating losses may require future financing, which could introduce dilution risk. Recent filings and transcripts do not indicate any major events or strategic shifts. The company continues to focus on its core segments and product development. There are no recent earnings calls or investor presentations that suggest a change in strategy or significant new product launches.